CLOs on the Move

ColoWrap

www.colowrap.com

 
ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.colowrap.com
  • 413, W Cornwallis Rd
    Durham, NC USA 27707
  • Phone: 919.451.1803

Executives

Name Title Contact Details

Similar Companies

Cahaba Family Medicine

Cahaba Family Medicine Residency is an unopposed, community-based family medicine training program dually accredited by both the ACGME and AOA. Resurrection Family Medicine is now the Cahaba Urban Residency.

Eisai

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Red Light Holland

Red Light Holland`s goal is to, over time, help make the relatively unknown `magic truffle` a familiar name across the world. We are currently setting up to grow, distribute and market a premium brand of magic truffles to the legal, recreational market within the Netherlands, and we can`t wait to shift the existing paradigm to direct further attention to the legal and responsible use of magic truffles.

Intouch Solutions

At Intouch Solutions, we know pharma marketing isn`t easy. But after more than a decade of hard work in this and similarly regulated industries, we think we understand that better than most. We have a pretty good idea of what it takes to connect your customers to your brand.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.